Dr. Mark Ware has devoted the past 20 years of his career to studying marijuana, and he can remember some “dark, lean” periods when he had to fight for meagre funding.
“There were times when I was told you couldn’t even use ‘cannabis’ and ‘research’ in the same sentence,” he recalled.
Now, Ware is the chief medical officer of one of Canada’s largest pot companies, Canopy Growth Corp., which is conducting millions of dollars worth of research on the use of cannabis to treat conditions including anxiety, insomnia and pain.
Legalization has sparked a boom in pot research, generating funding, jobs and the need for laboratory space. In the past, companies had little incentive to study an illicit substance, now they’re racing to create new products and prove their benefits.
Ware, also an associate professor of family medicine and anaesthesia at McGill University, said there have been brief funding windows over the years. When Canada legalized medical marijuana in the early 2000s, there was a flurry of interest, he said.
He said the current boom started in 2014 after the former Conservative government brought in legislation that established a commercial industry for medical marijuana. Companies have also been anticipating the legalization of recreational weed since the Liberal government came to power in 2015.
